Zydus Cadila’s needle-free, Covid-19 ZyCoV-D vaccine is a “plasmid DNA” vaccine and has been approved by the Drug Controller General of India (DGCI) to be given to children between the ages of 12-18 in India. It will be used with the help of the ‘Jet Injector’ technique in which instead of injecting the needle, the vaccine will use high-pressure stream of liquid that penetrates the outermost layer of the skin to deliver the vaccine to the underlying tissues of the epidermis.
ZyCov-D is a genetically engineered DNA plasmid (non-replicating version of a DNA molecule) based vaccine that carries the code for the SARS COV-2 virus. Plasmid helps to prepare a harmless version of the spike protein present on the SARS-COV-2 and induces the immune system to develop antibodies in response to the virus. It will be administered in three doses at an interval of 28 days.
World’s first plasmid DNA Covid Vaccine ZyCov-D has been tested in three clinical trials in over 28,000 volunteers and showed a minimum of 66.6% efficacy against symptomatic cases. In most cases, the efficacy is 100% and children are safe to be vaccinated. ZyCov-D is the sixth vaccine to get emergency use authorization in India. The company hopes to start the doses by the mid-week of September. Prices will be announced within few weeks.